Proposed Data Collections Submitted for Public Comment and Recommendations, 5658-5659 [E9-2002]
Download as PDF
<![CDATA[
5658
Federal Register / Vol. 74, No. 19 / Friday, January 30, 2009 / Notices
mstockstill on PROD1PC66 with NOTICES
eliminating direct and substantial
competition between Dow and Rohm &
Haas, by increasing Dow’s ability to
exercise market power unilaterally in
the relevant markets, and/or by
increasing the likelihood of coordinated
interaction in the markets for glacial
acrylic acid, butyl acrylate, and ethyl
acrylate. The Complaint further alleges
that potential new entry or fringe
expansion would not prevent the
anticompetitive effects described in the
Complaint.
III. Terms of the Proposed Order
Under the proposed Consent
Agreement, Dow will divest to a single
Commission-approved Acquirer a
significant part of its acrylic monomer
and polymer research and development
and production assets including: its
acrylic monomer production facility in
Clear Lake, Texas; its acrylic polymer
production assets located in St. Charles,
Louisiana; its acrylic polymer
production facility located in Alsip,
Illinois; its acrylic polymer production
facility located in Torrance, California;
its acrylic monomer research and
development group located in South
Charleston, West Virginia; its acrylic
latex polymer research and
development group located in Cary,
North Carolina, and other assets related
to such businesses. The divestiture
would also include the technology that
is primarily related to these businesses,
and further provides that Dow license to
the Acquirer any intellectual property
not primarily related to the divested
business that Dow nonetheless uses in
those businesses, and requires Dow to
divest the business contracts of the
divested businesses, and obtain the
consents that are necessary to assign
those contracts to the Acquirer. The
divestiture to a single acquirer of both
acrylic monomer and acrylic polymer
research, development, manufacture
and production assets best replicates the
pre-acquisition market structure in
which each of the significant acrylic
monomer firms was forward-integrated
into the supply of acrylic polymers.
In order to ensure the transition of the
divested assets and the viability of the
Acquirer, the Consent Agreement
requires Dow to provide certain
services. First, Dow is required to
continue to provide certain input
products to the Acquirer that Dow
provided previously to the divested
assets. Second, the Consent Agreement
requires Dow to provide transition
services for a short period of time to
accomplish the transition of the
divested assets to the Acquirer. Finally,
the Consent Agreement requires that
Dow continue to provide site services to
VerDate Nov<24>2008
16:54 Jan 29, 2009
Jkt 217001
the Acquirer in connection with the
acrylic polymer production assets
located in St. Charles, Louisiana, where
the Acquirer will operate a business
unit that, although largely separate, is
located on the grounds of a larger Dow
facility.
The Consent Agreement remedies the
competitive concerns in the markets for
hollow sphere particles and acrylic latex
polymer for traffic paint by requiring
Dow to divest the intellectual property
that is primarily related to these
products and to license certain other
intellectual property used for these
products. In addition, Dow is required
to supply hollow sphere particles and
acrylic latex polymer for traffic paint to
the Acquirer at its manufacturing cost,
until such time as the Acquirer is able
to develop its own manufacturing.
The Consent Agreement also requires
Dow to institute procedures to ensure
that it does not have access directly, or
indirectly, to competitively sensitive
non-public information obtained from
the Divested Businesses and Facilities
or to use any such competitively
sensitive non-public information it
already has in an anticompetitive
manner.
The proposed Order gives the
Commission the power to appoint an
interim monitor to assure that Dow
expeditiously complies with all of its
obligations and performs all of its
responsibilities as required by the
Order. If Dow fails to sell the divested
assets within the later of (1) 240 days
after the Consent Agreement is accepted
by the Commission for Public Comment
and (2) 240 days after the Acquisition
closes, the Order allows for the
appointment of a Divestiture Trustee to
divest the assets that are the subject of
the proposed Order. In order to ensure
that the Commission remains informed
about the status of the proposed
divestitures and the transfers of assets,
the proposed Consent Agreement
requires Dow to file reports with the
Commission periodically until the
divestitures and transfers are
accomplished.
The purpose of this analysis is to
facilitate public comment on the
proposed Decision and Order. This
analysis is not intended to constitute an
official interpretation of the Consent
Agreement and the proposed Decision
and Order.
By direction of the Commission.
Donald S. Clark
Secretary
[FR Doc. E9–2081 Filed 1–29–09: 8:45 am]
[BILLING CODE 6750–01–S]
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60-Day–09–09AM]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects.
Alternatively, to obtain a copy of the
data collection plans and instrument,
call 404–639–5960 and send comments
to Maryam I. Daneshvar, CDC Reports
Clearance Officer, 1600 Clifton Road,
NE., MS–D74, Atlanta, Georgia 30333;
comments may also be sent by e-mail to
omb@cdc.gov.
Comments are invited on (a) whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have a
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarify of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of information technology. Written
comments should be received within 60
days of this notice.
Proposed Project
Prevalence Survey of Healthcare
Acquired Infections (HAIs) in U.S.
Acute Care Hospitals—New—National
Center for Preparedness, Detection, and
Control of Infectious Diseases
(NCPDCID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
CDC is requesting OMB approval to
conduct a survey to obtain national
estimates of HAIs prevalence in the
United States. Preventing HAIs is a CDC
priority. An essential step in reducing
the occurrence of HAIs is to accurately
estimate the burden of these infections
in U.S. hospitals and to describe the
types of HAIs and their causative
organisms. The scope and magnitude of
HAIs in the U.S. were last directly
estimated in the 1970s and 1980s by
CDC’s Study on the Efficacy of
Nosocomial Infection Control (SENIC),
in which comprehensive data were
E:\FR\FM\30JAN1.SGM
30JAN1
5659
Federal Register / Vol. 74, No. 19 / Friday, January 30, 2009 / Notices
collected from a sample of 338
hospitals; 5% of hospitalized patients
acquired an infection not present at the
time of admission. Because of the
substantial resources necessary to
conduct hospital-wide surveillance in
an ongoing manner, CDC’s current HAI
surveillance system, the National
Healthcare Safety Network (NHSN),
focuses instead on device-associated
and procedure-associated infections in a
variety of patient locations, and does
not receive data on all types of HAIs to
make hospital-wide burden estimates.
The purpose of this data collection is to
assess the magnitude and types of HAIs
occurring in all patient populations
patients in the participating hospitals.
CDC will use the data provided to
estimate the prevalence of HAIs across
this representative sample of U.S.
hospitals as well as the distribution of
infection types and causative organisms.
CDC will also use this data to promote
its goal of preventing HAIs.
The proposed project supports CDC’s
Strategic Goal of ‘‘Healthy Healthcare
Settings,’’ specifically the objective to
‘‘Promote compliance with evidencebased guidelines for preventing,
identifying, and managing disease in
healthcare settings.’’ There are no costs
to respondents, other than their time to
complete the survey.
within acute care hospitals in order to
inform decisions by local and national
policy makers and hospital infection
control personnel regarding appropriate
targets and strategies for HAI
prevention. Such assessments can be
obtained in periodic national prevalence
studies, such as those that have been
conducted in several European
countries.
The proposed survey will be
conducted in a representative sample of
500 U.S. acute care hospitals, and will
require infection control personnel in
each participating hospital to collect
surveillance data on CDC-defined HAIs
on a single day for a sample of eligible
ESTIMATE OF ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Infection Control Practitioners .........................................................................
500
74
15/60
9,250
Total ..........................................................................................................
........................
........................
........................
9,250
Dated: January 22, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–2002 Filed 1–29–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day-09–0544]
Agency Forms Undergoing Paperwork
Reduction Act Review
mstockstill on PROD1PC66 with NOTICES
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an
e-mail to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
Proposed Project
NIOSH Customer Satisfaction
Survey—Reinstatement—National
Institute for Occupational Safety and
Health, (NIOSH) Centers for Disease
Control and Prevention, (CDC).
VerDate Nov<24>2008
16:54 Jan 29, 2009
Jkt 217001
Background and brief description
The mission of the National Institute
for Occupational Safety and Health
(NIOSH) is to promote safety and health
at work for all people through research
and prevention. The Occupational
Safety and Health Act, Public Law 91–
596 (section 20[a][1]) authorizes the
National Institute for Occupational
Safety and Health (NIOSH) to conduct
research to advance the health and
safety of workers. NIOSH conducted a
baseline survey in 2003 to assess
customer satisfaction with NIOSH
communication products, services, and
methods of dissemination [OMB #0920–
0544 expired 03/31/2003]. The baseline
survey established an initial benchmark
for gauging the effectiveness of NIOSH’s
communication products, outreach
services, and identified areas for
improvement.
NIOSH is conducting a follow-up
Customer Satisfaction Survey of
occupational safety and health
professionals. A mail survey is planned
with an option that will allow
respondents to complete the survey
electronically. The current survey is a 5year follow-up designed to enable
NIOSH to determine the current level of
customer satisfaction and identify
changes that have occurred in the
intervening years. The purpose of this
survey is to evaluate the effectiveness of
NIOSH’s communication and
dissemination program as a whole in
serving the broad occupational safety
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
and health professional community by
addressing five questions:
(1) To what extent are NIOSH
communication products viewed as
credible, useful sources of information
on occupational safety and health
issues?
(2) To what extent has NIOSH been
successful in distributing its
communication products to its primary
and traditional audience?
(3) To what extent, and in what ways,
have NIOSH communication products
influenced workplace safety and health
program policies and practices, or
resolved other related issues?
(4) What improvements could be
made in the nature of NIOSH
communication products and/or their
manner of delivery that could enhance
their use and benefits?
(5) What is the reach and perceived
importance of NIOSH outreach
initiatives?
The survey will be directed to the
community of occupational safety and
health professionals, as this audience
represents the primary and traditional
customer base for NIOSH information
materials. For this purpose four major
associations identified with
occupational safety and health matters
have indicated their willingness to
partner with NIOSH on this follow-up
survey, as they did on the baseline.
These are the American Industrial
Hygiene Association (AIHA), the
American College of Occupational and
Environmental Medicine (ACOEM), the
American Association of Occupational
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 74, Number 19 (Friday, January 30, 2009)]
[Notices]
[Pages 5658-5659]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2002]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60-Day-09-09AM]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
Alternatively, to obtain a copy of the data collection plans and
instrument, call 404-639-5960 and send comments to Maryam I. Daneshvar,
CDC Reports Clearance Officer, 1600 Clifton Road, NE., MS-D74, Atlanta,
Georgia 30333; comments may also be sent by e-mail to omb@cdc.gov.
Comments are invited on (a) whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have a practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarify of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of information technology. Written comments
should be received within 60 days of this notice.
Proposed Project
Prevalence Survey of Healthcare Acquired Infections (HAIs) in U.S.
Acute Care Hospitals--New--National Center for Preparedness, Detection,
and Control of Infectious Diseases (NCPDCID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
CDC is requesting OMB approval to conduct a survey to obtain
national estimates of HAIs prevalence in the United States. Preventing
HAIs is a CDC priority. An essential step in reducing the occurrence of
HAIs is to accurately estimate the burden of these infections in U.S.
hospitals and to describe the types of HAIs and their causative
organisms. The scope and magnitude of HAIs in the U.S. were last
directly estimated in the 1970s and 1980s by CDC's Study on the
Efficacy of Nosocomial Infection Control (SENIC), in which
comprehensive data were
[[Page 5659]]
collected from a sample of 338 hospitals; 5% of hospitalized patients
acquired an infection not present at the time of admission. Because of
the substantial resources necessary to conduct hospital-wide
surveillance in an ongoing manner, CDC's current HAI surveillance
system, the National Healthcare Safety Network (NHSN), focuses instead
on device-associated and procedure-associated infections in a variety
of patient locations, and does not receive data on all types of HAIs to
make hospital-wide burden estimates. The purpose of this data
collection is to assess the magnitude and types of HAIs occurring in
all patient populations within acute care hospitals in order to inform
decisions by local and national policy makers and hospital infection
control personnel regarding appropriate targets and strategies for HAI
prevention. Such assessments can be obtained in periodic national
prevalence studies, such as those that have been conducted in several
European countries.
The proposed survey will be conducted in a representative sample of
500 U.S. acute care hospitals, and will require infection control
personnel in each participating hospital to collect surveillance data
on CDC-defined HAIs on a single day for a sample of eligible patients
in the participating hospitals. CDC will use the data provided to
estimate the prevalence of HAIs across this representative sample of
U.S. hospitals as well as the distribution of infection types and
causative organisms. CDC will also use this data to promote its goal of
preventing HAIs.
The proposed project supports CDC's Strategic Goal of ``Healthy
Healthcare Settings,'' specifically the objective to ``Promote
compliance with evidence-based guidelines for preventing, identifying,
and managing disease in healthcare settings.'' There are no costs to
respondents, other than their time to complete the survey.
Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Respondents respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Infection Control Practitioners................. 500 74 15/60 9,250
---------------------------------------------------------------
Total....................................... .............. .............. .............. 9,250
----------------------------------------------------------------------------------------------------------------
Dated: January 22, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E9-2002 Filed 1-29-09; 8:45 am]
BILLING CODE 4163-18-P
